300086.SHE Hainan Honz Pharmaceutical Co
- Market cap
- CNY 2.19B
- P/E
- -
- P/B
- 2.55x
- ROE
- -12.3%
- Dividend yield
- 0.75%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300086.SHE undervalued?
Graham numberThe Graham number of Hainan Honz Pharmaceutical Co cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hainan Honz Pharmaceutical Co fundamental analysis
No fundamental analysis for Hainan Honz Pharmaceutical Co yet.
Hainan Honz Pharmaceutical Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough relief, anti-flu, antipyretic-analgesic, anti-infection, anti-fungal, endocrine,…
Full company profileHainan Honz Pharmaceutical Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hainan Honz Pharmaceutical Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 471M | 668M | 883M | 1.01B | 922M | 837M | 536M | 740M | 473M | 466M | 261M |
| Gross Profit | 194M | 276M | 390M | 474M | 470M | 418M | 266M | 441M | 247M | 253M | 136M |
| Operating Income | 48.2M | 67.4M | 34.1M | -19.1M | 58.0M | 21.4M | -213M | 25.0M | -222M | -160M | -77.9M |
| EBITDA | 95.5M | 118M | 99.8M | 57.0M | 98.3M | 78.8M | -144M | 126M | -148M | -174M | -79.2M |
| Net Income | 46.2M | 55.5M | 13.4M | -26.5M | 9.34M | 11.0M | -188M | 11.5M | -216M | -230M | -101M |
| EPS | 0.10 | 0.12 | 0.03 | -0.06 | 0.02 | 0.02 | -0.42 | 0.03 | -0.47 | -0.51 | -0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 2.19B | 2.24B | 2.18B | 2.19B | 2.61B | 2.46B | 2.29B | 2.17B | 1.98B | 1.79B | 1.67B |
| Total Liabilities | 317M | 315M | 527M | 593M | 1.01B | 905M | 933M | 788M | 811M | 870M | 823M |
| Shareholders' Equity | 1.80B | 1.85B | 1.54B | 1.50B | 1.50B | 1.50B | 1.32B | 1.34B | 1.14B | 900M | 824M |
| Cash & Short-term Investments | 193M | 133M | 84.2M | 186M | 258M | 259M | 270M | 144M | 113M | 59.8M | 5.77M |
| Total Debt | 100M | 100M | 210M | 239M | 649M | 593M | 583M | 502M | 400M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 90.9M | 18.2M | 158M | 45.1M | -16.7M | 11.3M | 29.3M | 70.7M | 71.5M | 121M | - |
| Capital Expenditure | 41.6M | 153M | 292M | 131M | 300M | 220M | 45.1M | 138M | 92.5M | 92.1M | 9.26M |
| Free Cash Flow | 49.3M | -135M | -134M | -85.9M | -316M | -209M | -15.8M | -66.9M | -21.0M | 29.1M | -59.0M |
| Ratios | |||||||||||
| ROE | 2.6% | 3.0% | 0.9% | -1.8% | 0.6% | 0.7% | -14.3% | 0.9% | -19.0% | -25.6% | -12.3% |
| ROA | 2.1% | 2.5% | 0.6% | -1.2% | 0.4% | 0.4% | -8.2% | 0.5% | -10.9% | -12.8% | -6.1% |
| Net Profit Margin | 9.8% | 8.3% | 1.5% | -2.6% | 1.0% | 1.3% | -35.0% | 1.6% | -45.7% | -49.4% | -38.7% |
| Debt to Equity | 0.06x | 0.05x | 0.14x | 0.16x | 0.43x | 0.39x | 0.44x | 0.37x | 0.35x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hainan Honz Pharmaceutical Co dividends
- Dividend yield
- 0.75%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 13, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 16.5M | 0.04 | - |
| 2024 | CNY 19.9M | 0.04 | - |
| 2023 | CNY 24.3M | 0.05 | 211.1% |
| 2022 | CNY 26.5M | 0.06 | - |
| 2021 | CNY 40.7M | 0.09 | 370.2% |
| 2020 | CNY 22.6M | 0.05 | 241.7% |
| 2019 | CNY 67.5M | 0.15 | - |
| 2018 | CNY 9.68M | 0.02 | 72.4% |
| 2017 | CNY 3.01M | 0.01 | 5.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on Sep 30, 2015.
Who owns Hainan Honz Pharmaceutical Co
- Insiders 32.78%
- Institutions 0.74%
- Public & others 66.48%
- Shares outstanding 455M
- Free float 335M
Hainan Honz Pharmaceutical Co company profile
- Company name
- Hainan Honz Pharmaceutical Co
- Ticker
- 300086.SHE
- ISIN
- CNE100000QM6
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 540
- Fiscal year end
- December
- Address
- No. 6, Yaogu Third Road, Haikou, China, 570311
- Phone
- 86 898 6866 1669
- Website
- honz.com.cn
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough relief, anti-flu, antipyretic-analgesic, anti-infection, anti-fungal, endocrine, anti-allergy, antibacterial and antiviral, respiratory system, digestive system, and gynecological indications, as well as nutritional supplements. It also provides maternal and infant health products; protective and medical masks; and medical devices, including medical protective equipment. In addition, the company engages in investment, property, planting, internet sales, and leasing activities. It markets its products through pharmaceutical distribution agents, sales terminals, and a marketing network. The company was formerly known as HaiNan Honz Pharmaceutical Co.,Ltd. and changed its name to Honz Pharmaceutical Co., Ltd. in November 2016. Honz Pharmaceutical Co., Ltd. was founded in 1993 and is headquartered in Haikou, China.
Hainan Honz Pharmaceutical Co management
5- Mr. Jiangyou HongChairman & President · born 1964
- Ms. Liping HongVice Chairman & VP · born 1968
- Ms. Jing LiCFO & Accounting Supervisor · born 1982
- Mr. Dexin LinVP & Board Secretary · born 1980
- Mr. Yong WangVice President · born 1977